BioCentury | Nov 10, 2020
Finance
Nov. 9 Quick Takes: Biogen sheds $14B in value; plus Ambrx’s 200M round, Decibel’s series D and more
...also included contributions from Panacea Venture, Kunlun Capital and SCVC.Memo raises $16M for COVID-19 programSwiss biotech Memo Therapeutics AG...
...intraday on Monday, still far below Thursday’s close at $15.90.TARGETSOTOF – Otoferlin BC Staff Decibel Therapeutics Biogen Ambrx Homology Pfizer Inmagene Biopharmaceuticals Co. Ltd. Memo Therapeutics Assembly...
...intraday on Monday, still far below Thursday’s close at $15.90.TARGETSOTOF – Otoferlin BC Staff Decibel Therapeutics Biogen Ambrx Homology Pfizer Inmagene Biopharmaceuticals Co. Ltd. Memo Therapeutics Assembly...
